Vivo Ventures is the lead investor in a $30 million funding of Shanghai Jingfeng Pharma, a maker of sodium hyaluronate; China National Pharma Group (Sinopharm) is having M&A discussions with European life science companies; Zhongyuan Union Stem Cell Bioengineering signed a stem cell venture MOU with Cell Therapy of Wales; Pioneer Pharma of Hong Kong completed a $2.5 million investment into California-based NovaBay® Pharma; Akeso Biopharma, a new China antibody drug discovery company, began operations in Zhongshan, drawn by aggressive incentives; Lundbeck of Denmark opened a $7.6 million production plant in Tianjin for its CNS drugs; and Mindray Medical reported higher Q2 revenues that were below analysts’ estimates. More details…. Stock Symbols: (SHA: 600645) (NYSE: NBY) (CPH: LUN) (NYSE: MR) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});